Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Welcome and Introduction to Vi3C

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Dec
03
Today In Oncology
Addition of Neoadjuvant LuPSMA PNT2002 to SBRT in Oligorecurrent Prostate Cancer
Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
Image-Only AI Model Outperforms Breast Density for 5-Year Breast Cancer Risk Stratification
Tisagenlecleucel in Relapsed or Refractory Large B-Cell Lymphoma
Retrospective Review Shows Persistent Breast Cancer Burden in Younger Women
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo